Dan Anderson is Chief Scientific Officer of Eikon Therapeutics and leads all drug discovery functions at the company.
Prior to joining Eikon, Dan was Vice President of Biology at Recursion Pharmaceuticals, a company industrializing phenotypic screening and using machine learning to disrupt drug discovery. He oversaw platform technology advancements and discovery program validation. Before joining Recursion, Dan worked at Cleave Biosciences as Head of Biology, he led the biology group working on novel targets in the oncology space. Dan began his biotechnology career at Genentech, where he led the group responsible for developing novel cellular and advanced microscopy assays to report on drug activity and mechanisms of action.
Dan earned his doctorate in cell biology and biochemistry from the University of California, San Diego. He has authored more than 20 publications and four patents.